Table 3.
Most commonly discussed impacts in the overall population and by disease stage
| Impact | Total (N = 30) | NDMM (n = 18) | RRMM (n = 12) |
|---|---|---|---|
| Daily life | 23 (77.0) | 14 (78.0) | 9 (75.0) |
| Physical activity | 22 (73.0) | 16 (89.0) | 6 (50.0) |
| Social life | 19 (63.0) | 10 (56.0) | 9 (75.0) |
| Emotional general | 15 (50.0) | 11 (61.0) | 4 (33.0) |
| Work | 10 (33.0) | 7 (39.0) | 3 (25.0) |
| Emotional anxiety | 8 (27.0) | 5 (28.0) | 3 (25.0) |
| Insomnia/sleep | 6 (20.0) | 5 (28.0) | 1 (8.0) |
| Family life | 6 (20.0) | 4 (22.0) | 2 (17.0) |
| Emotional depression | 3 (10.0) | 1 (6.0) | 2 (17.0) |
Data are presented as n (%). Impacts discussed in more than one interview; includes both spontaneous and prompted mentions; one or more “other” impacts (including cognitive issues, future planning, impact on studies, lack of motivation, mental capacity/time management, pain/medication, and sensitivity to foods) were mentioned in ten (33.0%) interviews
NDMM newly diagnosed multiple myeloma, RRMM relapsed/refractory multiple myeloma